Full-Time
Process Improvement Specialist
Posted on 8/19/2026
Ardent Health
10,001+ employees
Owns and operates acute care hospitals
No salary listed
Brentwood, TN, USA
In Person
Bachelor's
 Business & Strategy (1) |
|---|
Get referred to Ardent Health
See people who can refer or advise you
- A Bachelor's degree in Business, Health Administration, or a related field is required.
- At least 3 years of experience as a process engineer in the healthcare sector, including medical devices, pharmaceuticals, biotechnology, or healthcare services, is required.
- Strong knowledge of regulatory standards is required.
- Strong knowledge of Lean Six Sigma is required.
- Demonstrated success in process improvement projects with measurable impact is required.
- Strong data analysis and dashboarding skills using tools such as Power BI or Tableau are required.
- Strong communication, documentation, and project management skills are required.
- Lean Six Sigma certification must be obtained within one year of hire.
- Analyze, develop, and optimize service processes to improve efficiency, quality, and safety.
- Implement Lean Six Sigma methodologies to identify and eliminate waste and variability.
- Collaborate with cross-functional teams including Operations, Clinical Quality, Ambulatory, Information Technology, and the Enterprise Project Management Office.
- Support new team and organizational designs by developing scalable, compliant, and cost-effective processes.
- Develop and maintain process documentation, Standard Operating Procedures, and validation protocols in compliance with applicable regulations.
- Drive the implementation of process controls, automated solutions, and performance metrics.
- Evaluate and integrate new technologies or equipment as needed to enhance productivity.
- Develop and maintain comprehensive Standard Operating Procedures to reflect newly implemented processes and ensure consistent operational excellence.
Ardent Health Services operates a network of acute care hospitals and outpatient facilities in mid-sized urban communities across the United States, earning revenue from patient services. It expands by forming joint ventures with non-profit health systems and academic medical centers, and by growing ambulatory and urgent care clinics to funnel patients into its network. It standardizes operations with a single Epic electronic health record to unify information and improve efficiency, supporting a coordinated care network. Its goal is to build a scalable, integrated health system that improves access and continuity of care in its communities.
Company Size
10,001+
Company Stage
Post IPO Equity
Headquarters
Brentwood, Tennessee
Founded
1993
Get referred to Ardent Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $1.62 billion; operating cash flow jumped 67% to $197 million.
- IMPACT savings target rose to $70 million for 2026 under CEO Dave Caspers.
- Ardent reaffirmed 2026 EBITDA guidance on August 4, signaling resilient pricing and cost control.
What critics are saying
- Postiwala v. Ardent Health remains active; lead counsel was appointed June 26, 2026.
- Q2 2026 adjusted EBITDA fell 32.3%; management blamed lower surgeries and admissions.
- A revenue-recognition scandal would shatter payer trust, trigger reserves, and pressure refinancing.
What makes Ardent Health unique
- Ardent runs 30 hospitals across six states in growing mid-sized urban markets.
- Eighteen hospitals sit in joint ventures with nonprofits and academic medical centers.
- Epic standardization and Fujifilm Synapse integration unify inpatient, outpatient, and imaging workflows.
Help us improve and share your feedback! Did you find this helpful?
Growth & Insights and Company News
6 month growth
↑ 11%1 year growth
↑ 11%2 year growth
↑ 11%Ardent Health reported second-quarter 2026 results with total revenue of $1.62 billion and net income of $17 million. The healthcare provider posted adjusted EBITDA of $115 million, whilst admissions decreased 1.0% year-over-year, though adjusted admissions grew 2.5%. Operating cash flow reached $197 million, up 67% from the prior year. The company reaffirmed its full-year 2026 guidance, projecting total revenue between $6.4 billion and $6.7 billion and adjusted EBITDA of $485 million to $535 million. CEO Dave Caspers said second-quarter performance was impacted by lower surgeries and admissions but noted volumes improved following early June. The company expects its IMPACT programme to generate at least $70 million in savings for 2026, up from a previous estimate of $55 million.
Ardent Health (NYSE:ARDT) issues earnings results. August 4, 2026 Key points. * Ardent Health missed quarterly earnings expectations: The company reported $0.12 in EPS versus the $0.18 consensus estimate, while revenue of $1.62 billion exceeded expectations of $1.59 billion. FY 2026 EPS guidance was updated to $0.78-$1.15. * Shares edged down 0.1% to $10.74 following the results, with the stock trading below its 52-week high of $15.48. Ardent Health has a market capitalization of approximately $1.54 billion. * Analyst sentiment remains mixed: Seven analysts rate the stock Buy, five Hold, and two Sell, producing a consensus Hold rating and an average price target of $14.04. CFO Alfred Lumsdaine also purchased 10,000 shares, increasing his holdings by 3.13%. * MarketBeat previews the top five stocks to own by September 1st. Ardent Health (NYSE:ARDT - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.06), FiscalAI reports. Ardent Health had a return on equity of 13.85% and a net margin of 2.09%.The firm had revenue of $1.62 billion for the quarter, compared to analysts' expectations of $1.59 billion. Ardent Health updated its FY 2026 guidance to 0.780-1.150 EPS. Ardent Health trading down 0.1%. ARDT traded down $0.01 during trading hours on Tuesday, reaching $10.74. 413,105 shares of the company's stock traded hands, compared to its average volume of 461,909. The firm has a 50-day moving average price of $9.83 and a 200 day moving average price of $9.43. The firm has a market capitalization of $1.54 billion, a PE ratio of 11.30, a PEG ratio of 2.51 and a beta of 0.70. The company has a quick ratio of 2.00, a current ratio of 2.12 and a debt-to-equity ratio of 0.62. Ardent Health has a 52-week low of $7.71 and a 52-week high of $15.48. Wall Street analysts forecast growth. ARDT has been the subject of several research reports. Royal Bank Of Canada lowered their price objective on shares of Ardent Health from $13.00 to $12.00 and set an "outperform" rating for the company in a research report on Thursday, July 9th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Ardent Health in a report on Friday, June 12th. Wall Street Zen cut Ardent Health from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. UBS Group raised their price objective on Ardent Health from $13.00 to $13.50 and gave the company a "buy" rating in a research note on Thursday, May 7th. Finally, Truist Financial lowered their price target on Ardent Health from $13.00 to $12.00 and set a "buy" rating for the company in a research report on Tuesday, July 14th. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $14.04. Discover more text messages Insider buying and selling at Ardent Health. In related news, CFO Alfred Lumsdaine bought 10,000 shares of the stock in a transaction dated Friday, June 5th. The stock was purchased at an average cost of $8.81 per share, with a total value of $88,100.00. Following the completion of the purchase, the chief financial officer owned 329,183 shares of the company's stock, valued at $2,900,102.23. This trade represents a 3.13% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.90% of the company's stock. Institutional investors weigh in on Ardent Health. A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. grew its stake in Ardent Health by 24.4% in the 4th quarter. Invesco Ltd. now owns 71,304 shares of the company's stock worth $630,000 after acquiring an additional 13,964 shares in the last quarter. Empowered Funds LLC raised its stake in shares of Ardent Health by 135.0% during the fourth quarter. Empowered Funds LLC now owns 551,738 shares of the company's stock valued at $4,872,000 after acquiring an additional 316,961 shares in the last quarter. VARCOV Co. bought a new stake in shares of Ardent Health during the fourth quarter valued at approximately $232,000. Susquehanna Portfolio Strategies LLC boosted its holdings in shares of Ardent Health by 101.8% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 62,957 shares of the company's stock valued at $556,000 after purchasing an additional 31,758 shares during the period. Finally, Numerai GP LLC purchased a new stake in shares of Ardent Health in the fourth quarter valued at approximately $616,000. About Ardent Health. Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company's integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs. Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Ardent Health, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ardent Health wasn't on the list. While Ardent Health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Ardent Health has appointed former Chief Operating Officer Dave Caspers as President and CEO, succeeding Marty Bonick following the company's post-IPO transformation. Caspers will also join the board and oversee Ardent's IMPACT margin and care transformation programme. The leadership change maintains the company's operational focus on improving hospital efficiency and building outpatient scale in mid-sized markets. Ardent recently reaffirmed its full-year 2026 adjusted EBITDA guidance despite softer second-quarter volumes. The company's narrative projects $7.2 billion revenue and $206.4 million earnings by 2029, requiring 4% yearly revenue growth. However, investors face risks from payer denials, labour costs, regulatory uncertainty and heavy reliance on Medicaid supplemental programmes. Analysts' forecasts suggest a $12.50 fair value, representing 44% upside from current prices.
New Ardent Health CEO inherits growth ambitions. Ardent elevated its former COO, Dave Caspers, to the top job as the Tennessee-based system grapples with its declining stock price.
Arden Health - Marty Bonick steps down as CEO. Tuesday, Jun 2, 2026 4:15 pm ET 1min read Ardent Health (NYSE: ARDT) has announced that Marty Bonick, president and chief executive officer, will step down from his role as CEO, marking a significant leadership transition for the healthcare provider. With nearly 25 years of healthcare leadership experience, Bonick has played a pivotal role in transforming Ardent's operations, focusing on improving patient care and operational efficiency across its 30 hospitals and more than 280 sites of care. Bonick joined Ardent in 2020 and previously held leadership roles at PhyMed Healthcare Group, Community Health Systems, and Jewish Hospital & St. Mary's Healthcare. His tenure at Ardent has been marked by strategic growth initiatives and a commitment to innovation in healthcare delivery. In addition to his role at Ardent, Bonick has served on multiple healthcare-related boards, including the Federation of American Hospitals and the Nashville Health Care Council. The company has not yet announced a successor or provided details on the transition timeline. Ardent's board of directors, which recently welcomed Robert DeMichiei, a seasoned healthcare finance executive, will likely play a key role in the next phase of leadership planning. Bonick's departure comes amid a period of continued investment in healthcare infrastructure, including major hospital construction projects and digital transformation efforts. Ardent remains focused on expanding access to care in mid-sized urban communities across the U.S. Investors will be watching closely for updates on leadership continuity and strategic direction as the company moves forward. Ask Aime: What is the impact of Marty Bonick's departure on Ardent Health's stock performance and leadership strategy? Aime insights. Which stocks are commonly held by Cathie Wood and Pelosi? Give me three stocks in an uptrend with cumulative gains not exceeding 20% in the last month? What powerful indicators do day traders use? What's the performance trend of major Indian companies listed on US stock exchanges?